Patients' characteristics at recurrence disease before olaparib maintenance
| Overall population (n=209) | No surgery (n=137) | Surgery (n=72) | P-value | ||||
| Age at relapse before olaparib, median (IQR) | 57.7 | (51.1–63.0) | 57.9 | (52.4–62.8) | 57.1 | (49.8–63.5) | 0.52 |
| First-line PFI>12 months, n (%) | 0.66 | ||||||
| No | 57 | (27.3) | 36 | (26.3) | 21 | (29.2) | |
| Yes | 152 | (72.7) | 101 | (73.7) | 51 | (70.8) | |
| ECOG PS, n (%) | 0.01 | ||||||
| 0 | 157 | (75.1) | 95 | (69.3) | 62 | (86.1) | |
| 1 | 43 | (20.6) | 33 | (24.1) | 10 | (13.9) | |
| Type of BRCA mutation, n (%) | |||||||
| BRCA 1 | 143 | (68.4) | 96 | (70.1) | 47 | (65.3) | 0.33 |
| BRCA 2 | 65 | (31.1) | 41 | (29.9) | 24 | (33.3) | |
| Both BRCA 1/2 | 1 | (0.5) | 0 | (0.0) | 1 | (1.4) | |
| Residual tumor at surgery at recurrence before olaparib, n (%) | |||||||
| RT=0 | 60 | (28.7) | NA | 60 | (83.3) | ||
| RT <1 | 2 | (1.0) | NA | 2 | (2.8) | ||
| RT ≥1 | 10 | (4.8) | NA | 10 | (13.9) | ||
| Centers, n (%) | <0.001 | ||||||
| Site 1 | 16 | (7.7) | 12 | (8.8) | 4 | (5.6) | |
| Site 2 | 3 | (1.4) | 2 | (1.4) | 1 | (1.4) | |
| Site 3 | 15 | (7.2) | 15 | (10.9) | 0 | (0.0) | |
| Site 4 | 19 | (9.1) | 19 | (13.9) | 0 | (0.0) | |
| Site 5 | 28 | (13.4) | 11 | (8.0) | 17 | (23.6) | |
| Site 6 | 33 | (15.8) | 21 | (15.3) | 12 | (16.6) | |
| Site 7 | 16 | (7.7) | 9 | (6.6) | 7 | (9.7) | |
| Site 8 | 14 | (6.7) | 9 | (6.6) | 5 | (6.9) | |
| Site 9 | 35 | (16.7) | 23 | (16.8) | 12 | (16.6) | |
| Site 10 | 5 | (2.4) | 4 | (2.9) | 1 | (1.4) | |
| Site 11 | 7 | (3.3) | 7 | (5.1) | 0 | (0.0) | |
| Site 12 | 14 | (6.7) | 3 | (2.2) | 11 | (15.3) | |
| Site 13 | 4 | (1.9) | 2 | (1.4) | 2 | (2.7) | |
| N.CT before olaparib, n (%) | 0.007 | ||||||
| 1 | 94 | (45.0) | 57 | (41.6) | 37 | (51.4) | |
| 2 | 93 | (44.5) | 59 | (43.1) | 34 | (47.2) | |
| >3 | 22 | (10.5) | 21 | (15.3) | 1 | (1.4) | |
| CT before olaparib, n (%) | 0.07 | ||||||
| Carboplatinum | 33 | (15.8) | 16 | (11.7) | 17 | (23.6) | |
| Carbo + gem | 66 | (31.6) | 46 | (33.6) | 20 | (27.8) | |
| Carbo + gem + beva | 2 | (1.0) | 1 | (0.7) | 1 | (1.4) | |
| Carbo + paclitaxel | 15 | (7.2) | 9 | (6.6) | 6 | (8.3) | |
| Carbo + PLD | 64 | (30.6) | 40 | (29.2) | 24 | (33.3) | |
| Cis | 21 | (10.0) | 19 | (13.9) | 2 | (2.8) | |
| Cis + paclitaxel | 1 | (0.5) | 0 | (0.0) | 1 | (1.4) | |
| Oxaliplatin | 1 | (0.5) | 1 | (0.7) | 0 | (0.0) | |
| Other | 6 | (2.9) | 5 | (3.6) | 1 | (1.4) | |
Beva, bevacizumab; Carbo, carboplatinum; Cis, cisplatin; CT, chemotherapy; Gem, gemcitabine; IQR, interquantile range; PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin; RT, residual tumor.